Look back at pharma news to Sept 15

17 September 2017

By Barbara Obstoj-Cardwell

Halozyme Therapeutics hit the headlines big-time last week, announcing deals with two of the largest global drugmakers that could earn the company as much as $2 billion over the coming years. Also, Germany’s Bayer gained approval in the USA for its non-Hodgkin lymphoma drug Aliqopa, Israel’s Teva Pharmaceutical Industries scored a hit, hiring Lundbeck chief executive to head the rudderless company, along with the sale of its Paragard, UK-based AstraZeneca presented very encouraging data from the PACIFIC study on its durvalumab, while America’s Amicus Therapeutics announced the failure of its rare skin diseases drug candidate SD-101.

Halozyme hits the big time

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK